Clinical Trials
174
Active:10
Completed:43
Trial Phases
6 Phases
Early Phase 1:7
Phase 1:2
Phase 2:5
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (131 trials with phase data)• Click on a phase to view related trials
Not Applicable
90 (68.7%)Phase 4
21 (16.0%)Early Phase 1
7 (5.3%)Phase 3
6 (4.6%)Phase 2
5 (3.8%)Phase 1
2 (1.5%)Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting
Not yet recruiting
- Conditions
- Ischemic Stroke
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Target Recruit Count
- 839
- Registration Number
- NCT07028775
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension
Not Applicable
Not yet recruiting
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 410
- Registration Number
- NCT06987097
Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients
Not Applicable
Not yet recruiting
- Conditions
- HypoxiaObesityGastrostomy
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Target Recruit Count
- 364
- Registration Number
- NCT06966934
Determination of the Optimal Volume of Liposomal Bupivacaine in Adductor Canal Block for Knee Joint Surgery
Phase 4
Recruiting
- Conditions
- Optimal Volume of Liposomal Bupivacaine
- Interventions
- Drug: Perform adductor canal block with liposomal bupivacaine.
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-06-22
- Target Recruit Count
- 63
- Registration Number
- NCT06942689
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Recruiting
- Conditions
- Lung CancersPancreatic CancerNeuroendocrine TumorsThyroid Cancer
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 20
- Registration Number
- NCT06937112
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 35
- Next
News
No news found